Comparison of therapeutic particle ranges, LET, and DNA damage potencies (made in Canva). Credit: Targeted Oncology (2024). DOI: 10.1007/s11523-024-01071-y A new approach to treating the most malignant type of brain cancer—glioblastoma—has shown strong promise in pre-clinical settings, raising hopes of increasing current average survival rates beyond 18 months. Targeted alpha therapy (TAT) is emerging as a potential additional treatment for glioblastoma (GB), a disease which has confounded oncologists for decades due to its aggressive nature and strong resistance to existing therapies. The current standard treatment for GB is surgery, followed Read More